EVERVIE HEALTH LIMITED

(Formerly known as PVP Ventures Limited)

Date: 13th November, 2026

To,

National Stock Exchange of India Limited The Manager, Listing Department Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai - 400051 **Equity- Symbol: PVP** **Debt - 18PVL29A, 18PVL29**	**BSE Limited** Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001 **Equity- Scrip Code: 517556**

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on 13th November, 2026

In continuation of our letter dated 6th November, 2026, and pursuant to Regulations 30, 33, 52 and 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., Friday, 13th November, 2026, has, inter-alia, considered and approved the following:

1. **Unaudited Standalone and Consolidated Financial Results**

   The Board approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended 30th September, 2026, along with the Statement of Assets and Liabilities, Statement of Cash Flows and disclosures under Regulation 52(4), as reviewed and recommended by the Audit Committee at its meeting held earlier today. The said Financial Results, together with the Limited Review Reports issued by the Statutory Auditors of the Company, are enclosed as **Annexure 1.**

2. **Security Cover Certificate**

   Pursuant to Regulation 54(3) of the Listing Regulations, the Security Cover Certificate in respect of the listed Non-Convertible Debentures of the Company for the quarter and half-year ended 30th September, 2026 is enclosed as **Annexure 2.**

The Board Meeting commenced at 6:15 P.M. and concluded at 6:45 P.M. You are requested to kindly take the above information on record.

Thanking You,

Yours faithfully,
For Evervie Health Limited

(Formerly Known as PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:32:00 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Annexure I

Evervie Health Limited (formerly PVP Ventures Limited)

Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031

Web: www.evervichealth.com

CIN:L72300TN1991PLC020122

Statement of Standalone unaudited Financial Results for the quarter and half year ended 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

Sl No	Particulars	Quarter ended			Half year ended		Year ended
		September 2026 (Unaudited)	June 2026 (Unaudited)	September 2025 (Unaudited)	September 2026 (Unaudited)	September 2025 (Unaudited)	March 2026 (Audited)
1	**Income**						
	(a) Revenue from operations	1,112.83	1,349.27	506.96	2,462.10	1,426.24	3,292.29
	(b) Other Income	311.95	2,542.93	359.73	2,854.88	716.30	2,049.26
	Total Income (1)	**1,424.78**	**3,892.20**	**866.69**	**5,316.98**	**2,142.54**	**5,341.55**
2	**Expenses**						
	(a) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	65.08	82.60	71.93	147.68	143.90	264.72
	(b) Employee benefit expenses	131.72	73.77	90.42	205.49	240.45	416.47
	(c) Finance Cost	931.43	890.18	815.56	1,821.61	1,621.31	3,154.31
	(d) Depreciation and Amortization Expenses	26.16	27.68	13.75	53.84	28.05	94.36
	(e) Other Expenses	164.89	236.77	407.95	401.66	626.36	1,001.39
	Total Expenses (2)	**1,319.28**	**1,311.00**	**1,399.61**	**2,630.28**	**2,660.07**	**4,931.25**
3	**Profit/(Loss) before exceptional items and tax (1-2)**	**105.50**	**2,581.20**	**(532.92)**	**2,686.70**	**(517.53)**	**410.30**
4	Exceptional Loss / (Gain)	-	1,085.00	-	1,085.00	-	305.53
5	**Profit/ (Loss) before tax (3-4)**	**105.50**	**1,496.20**	**(532.92)**	**1,601.70**	**(517.53)**	**104.77**
6	**Tax expense**						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	(80.44)	(14.96)	(202.80)	(95.40)	(265.61)	(34.92)
	c) Prior period deferred tax	-	-	67.37	-	67.37	67.37
	d) Income tax for earlier years	-	-	-	-	-	-
	Total Tax expense	**(80.44)**	**(14.96)**	**(135.43)**	**(95.40)**	**(198.24)**	**32.45**
7	**Net Profit / (Loss) for the period / year (5-6)**	**185.94**	**1,511.16**	**(397.49)**	**1,697.10**	**(319.29)**	**72.32**
8	**Other Comprehensive Income**						
	(A) Item that will not be reclassified to Profit or Loss						
	(i) Remeasurement of the defined benefit liability	-	-	-	-	-	7.24
	(ii) Income tax expenses relating to the above	-	-	-	-	-	-
		-	-	-	-	-	7.24
	(B) Items that will be reclassified to Profit or Loss						
	(i) Fair value gain/(loss) on equity investments classified as FVTOCI	-	-	34.21	-	47.83	309.49
	(ii) Income tax expenses relating to the above	-	-	-	-	-	-
		-	-	**34.21**	-	**47.83**	**309.49**
	Total Other Comprehensive Income/ (Loss) (8)	-	-	**34.21**	-	**47.83**	**316.73**
9	**Total Comprehensive Income / (Loss) (7+8)**	**185.94**	**1,511.16**	**(363.28)**	**1,697.10**	**(271.46)**	**389.05**
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37
11	Reserves (Other Equity)						(4,656.71)
12	Earnings per share (Face Value of Rs. 10/- each)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic (in Rs.)	0.07	0.58	(0.15)	0.65	(0.12)	0.03
	(b) Diluted (in Rs.)	0.07	0.58	(0.15)	0.65	(0.12)	0.03

Place : Hyderabad
Date : 13-11-2026

CNGSN & ASSOCIATES LLP CHENNAI CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:18:03 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervichealth.com
CIN:L72300TN1991PLC020122

Notes to Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

1 The above standalone unaudited Financial Results of Evervie Health Limited (formerly PVP Ventures Limited) ('the Company') for the quarter and half year ended 30 September 2026 have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") as prescribed under Section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements Regulations), 2015, as amended, ("the Listing Regulations") which were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 13 November 2026. The Statutory Auditors of the Company have carried out Limited Review of the results for the quarter and half year ended 30 September 2026.

2 The Company had invested in 24,832; 22% Secured Redeemable Non-Convertible Debentures (NCDs) of Rs. 100,000 each issued by New Cyberabad City Projects Private Limited ("NCCPL"), erstwhile subsidiary and currently a related party of the Company. Further, on 16 March 2015 the said investment of Rs. 24,832 Lakhs in debentures was converted to an Interest Free Secured loan against the security of Land owned by NCCPL and Land development rights available with NCCPL , repayable on 31 March 2017 which was further extended by 10 years to 31 March 2027. A further extension of 1 year until 31 March 2028 was granted vide supplementary agreement dated 07 February 2024. The outstanding principal loan amount as on 30 September 2026 is Rs. 21,843.49 Lakhs.

Though NCCPL is not carrying any business activity, based on the below-mentioned factors, the Company believes that while there could be a further extension of the tenor beyond the stipulated date of 31 March 2028, the amounts are fully recoverable and hence there is no necessity to create an allowance for Expected Credit Loss.

i. Market value of a nearby land serving as a proxy to the land over which development rights held by NCCPL.
ii. Business plans of NCCPL to monetise the land bank by developing residential and/or commercial properties.
iii. Enforceable clause in the Share Purchase Agreement (SPA) which provides the first priority repayment of the loan based on the cash flows to be generated out of the project to be developed as stated in (ii) above. Additionally, the Company is guaranteed 50% payout from the revenues generated in excess of the loan outstanding, out of the sale/development of the aforesaid properties.

The Company believes that the provisions of Section 186(1) & 188 of the Act have been complied with to the extent applicable.

Further based on internal assessment/professional opinion received in this regard, the other provisions of Section 186 of the Act in respect to loans, making investments, providing guarantees and securities are not applicable to the Company as it is involved in the business of providing infrastructural facilities.

3 The Company was treating the aforesaid loan as deemed investment in subsidiary and hence was carrying the same at cost until 30 September 2023. Consequent to NCCPPL ceasing to be a subsidiary as highlighted above, the Company has carried the same at amortized cost as at 30 September 2026 in accordance with the requirements of Ind AS-109 – Financial instruments. Accordingly, the Management has carried the loan at present value by discounting the future cash flows at a rate of 8% over an estimated repayment period of 8.5 years (considering the possibility of further extension as stated above as against the balance legal tenor of 4 years).

The accounting has been done in the following manner:

Particulars	Remarks	Amount upon initial recognition	Amount carried as at 30 September 2026
Carried as Loan under Non-Current financial assets	Interest income has been recorded under the Effective Interest Rate (EIR) method*	11,091.29	14,088.56
Carried as Prepayment asset under other Non-Current Assets	Amortization would be done in proportion of revenues accruing to the Company as per the SPA as stated in Note 2 (iii) above	10,752.20	10,752.20
		21,843.49	

* An amount of Rs. 303.03 Lakhs and Rs. 550.63 Lakhs has been recognized as Interest Income under Other Income for the quarter and half year ended 30 September 2026 respectively.

4 During the quarter ended 30 June 2026, the Company acquired additional 4,263 shares representing a additional stake of 7.99% of the paid up share capital of 7Med India Private Limited (7 Med) for a consideration of Rs. 1,926.24 Lakhs. Accordingly, the Company now holds 41.23% in 7 Med. The effective date of additional investment has been considered as 1 April 2026.

5 The Company had acquired Humain Healthtech Private Limited ("HHT") in October 2023. HHT, in turn, has two subsidiaries, namely Noble Diagnostics Private Limited ("Noble") and Apta Medical Imaging Private Limited ("Apta").

The investment in HHT is carried at cost in the standalone financial statements and is subject to impairment assessment in accordance with Ind AS 36, Impairment of Assets. Accordingly, the Company carried out an impairment assessment of its investment in HHT based on the estimated recoverable amount, considering the future business plans and projected cash flows of the underlying business. Based on the assessment, the recoverable amount was determined to be lower than the carrying amount of the investment due to negative net-worth of Apta.

Consequently, an impairment loss of ₹1,085.00 lakhs has been recognised against the investment in HHT during the quarter ended 30 June 2026. The impairment loss has been presented as an exceptional item in the Statement of Profit and Loss.

6 Subsequent to the half year ended 30 September 2026, the name of the Company has been changed from "PVP Ventures Limited" to "Evervie Health Limited" with effect from 05 October 2026, pursuant to the fresh Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre. The Corporate Identity Number (CIN) of the Company remains unchanged.

7 As per Ind AS-108 "Operating Segment", the Company has disclosed the segment information only as part of the Consolidated unaudited Financial Results for the quarter and half year ended 30 September 2026.

8 The Statement of Standalone Assets and Liabilities as at 30 September 2026 and Statement of Standalone Cash flows for the half year ended 30 September 2026 are provided in Annexure 1 & 2 respectively.

9 Previous period figures have been reclassified to conform to the current period classification/presentation.

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:18:28 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

CNGSN & ASSOCIATES LLP CHENNAI CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

Place : Hyderabad
Date : 13-11-2026

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervіehealth.com
CIN:L72300TN1991PLC020122

Annexure 1 - Statement of Standalone Assets and Liabilities as at 30 September 2026
(All amounts are in Lakhs Indian Rupees unless otherwise stated)

	Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
I	**ASSETS**		
(1)	**Non Current Assets**		
	(a) Property, Plant and Equipment	359.17	382.83
	(b) Right of use Assets	100.15	126.55
	(c) Financial Assets		
	(i) Investments	17,830.86	17,990.25
	(ii) Loans	14,088.56	13,537.93
	(iii) Other financial assets	2,154.93	2,022.67
	(d) Income Tax Asset (net)	150.00	150.00
	(e) Deferred Tax Assets (net)	686.51	591.12
	(f) Other Non-Current Assets	12,204.07	12,204.07
	Total Non Current Assets	**47,574.25**	**47,005.42**
(2)	**Current assets**		
	(a) Inventories	4,608.18	4,755.86
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	221.64	127.23
	(iii) Cash and Cash Equivalents	1,023.56	21.71
	(iv) Other Bank Balances	428.97	26.60
	(v) Loans	7.37	20.93
	(vi) Other Financial Assets	415.90	3.39
	(c) Other current assets	122.02	69.85
	Total Current Assets	**6,827.64**	**5,025.57**
	Total Assets	**54,401.89**	**52,030.99**
II.	**EQUITY AND LIABILITIES**		
A	**EQUITY**		
	(a) Equity Share Capital	26,040.37	26,040.37
	(b) Other Equity	(2,959.61)	(4,656.71)
	Total Equity	**23,080.76**	**21,383.66**
B	**LIABILITIES**		
(1)	**Non Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	10,951.49	12,978.15
	(ii) Lease Liabilities	81.73	113.69
	(iii) Other Financial Liabilities	-	-
	(b) Provisions	15.66	14.63
	(c) Other non current liabilities	9,859.48	8,589.89
	Total Non Current Liabilities	**20,908.36**	**21,696.36**
(2)	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	9,370.50	7,620.59
	(ii) Lease Liabilities	63.15	58.99
	(iii) Trade payables		
	- Total Outstanding dues to Micro and Small Enterprises	2.40	2.96
	- Total Outstanding dues to creditors other than Micro and Small Enterprises	105.12	126.40
	(iv) Other financial liabilities	25.15	22.46
	(b) Other current liabilities	524.86	786.64
	(c) Provisions	-	1.03
	(d) Current Tax Liabilities (Net)	321.59	331.90
	Total Current Liabilities	**10,412.77**	**8,950.97**
	Total Liabilities	**31,321.13**	**30,647.33**
	Total Equity and Liabilities	**54,401.89**	**52,030.99**

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:19:22 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Place : Hyderabad
Date : 13-11-2026

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervichealth.com
CIN:L72300TN1991PLC020122

Annexure 2 - Statement of Standalone Cashflow for the half year ended 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

	Particulars	For the half year ended 30 September 2026 Unaudited	For the year ended 31 March 2026 Audited
I	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Profit / (Loss) before Tax	**1,601.70**	**104.77**
	Adjustments for:		
	Loss on sale of investment	-	305.53
	Provision for impairment of investment	1,085.00	-
	Depreciation and Amortization	53.84	94.36
	Provision for Diminution in value of Investments	-	-
	Miscellaneous income	-	-
	Interest Income	(2.54)	(151.27)
	Liabilities no longer required written back	-	(500.05)
	Provision for Advances no longer required written back	(2,238.46)	(242.92)
	Interest Income on Financial Assets	(613.25)	(1,155.02)
	Assets written off	-	4.89
	Finance Cost	1,821.61	3,154.31
	Operating profit / (Loss) before working capital / other changes	**1,707.90**	**1,614.60**
	Adjustments for (increase) / decrease in operating assets:		
	Trade Receivables	(94.41)	(123.83)
	Loans	2,252.01	(9.03)
	Inventories	147.68	264.01
	Other non-current financial assets	(69.63)	(457.68)
	Other current financial assets	(412.51)	(2.86)
	Other non-current assets	-	71.00
	Other current assets	(52.17)	765.47
	Adjustments for increase / (decrease) in operating liabilities:		
	Trade Payables	(21.84)	554.49
	Other non-current Financial Liabilities	-	(647.49)
	Other current financial liabilities	2.69	(13.02)
	Non-current provisions	1.03	(85.82)
	Current provisions	(1.03)	(0.15)
	Other non-current liabilities	1,269.59	(1,527.76)
	Other current liabilities	(261.78)	(180.97)
	Cash Generated From Operations	**4,467.53**	**220.96**
	Direct Taxes Paid (net)	(10.31)	(16.59)
	Net Cash Flow From Operating Activities	**4,457.22**	**204.37**
II	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Capital expenditure towards tangible assets (including Capital advances, net of capital creditors)	(3.78)	(208.12)
	Proceeds from redemption of debentures	-	-
	Acquisition of subsdiaries	(1,926.24)	(14,145.31)
	Advance paid for acquisition of subsidiary	-	-
	Loans to related parties (net) - repayment/(granted)	1,040.63	(1,221.46)
	Investment in equity shares of other entities	(40.00)	-
	Proceeds from sale of subsidiaries	-	-
	Proceeds from sale of investments	-	220.53
	Interest income received	2.57	150.23
	Movement in other bank balances not considered as cash & cash equivalents	(402.37)	(26.60)
	Net Cash Flow From / (Used in) Investing Activities	**(1,329.19)**	**(15,230.73)**

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervichealth.com
CIN:L72300TN1991PLC020122

Annexure 2 - Statement of Standalone Cashflow for the half year ended 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

	Particulars	For the half year ended 30 September 2026 Unaudited	For the year ended 31 March 2026 Audited
III	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Non convertible debentures (NCD's) issued	-	15,000.00
	Long term borrowings (repaid)/taken	829.94	1,510.14
	Short term borrowings taken / (repaid) (net)	(1,153.01)	(977.84)
	Payment of Lease Liabilities	(41.50)	(50.72)
	Finance costs paid	(1,761.61)	(474.20)
	Net Cash Flow From / (Used in) Financing Activities	**(2,126.18)**	**15,007.38**
IV	**Net (Decrease) / Increase in Cash and Cash Equivalents (I + II + III)**	1,001.85	(18.98)
V	**Cash and Cash Equivalents at the beginning of the year**	21.71	40.69
VI	**Cash and Cash Equivalents at the end of the year (V + VI)**	**1,023.56**	**21.71**

Place : Hyderabad
Date : 13-11-2026

CNGSN & ASSOCIATES LLP CHENNAI CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:22:31 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervichealth.com

CIN:L72300TN1991PLC020122

Additional disclosure as per Regulation 52 (4) and 54 (2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, for the quarter and half year ended 30 September 2026

S.No.	Particulars	Quarter ended			Half year ended		Year ended
		September 2026	June 2026	September 2025	September 2026	September 2025	March 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Debt-Equity ratio** (Total Borrowings/Total Equity)	0.88	0.91	0.90	0.88	0.90	0.96
2	**Debt service coverage ratio** (Profit before tax + depreciation + finance cost))/(over next one year - Expected interest outflow on long term borrowings including redemption premium +lease payements+Principal repayments)	0.09	0.39	0.03	0.30	0.13	0.42
3	**Interest service coverage ratio** (Profit before tax + depreciation + finance cost))/(over next one year - Expected interest outflow on long term borrowings including redemption premium)	0.45	0.66	0.05	1.53	0.21	0.85
4	**Current ratio** Current assets/Current liabilities	0.66	0.73	1.61	0.66	1.61	0.56
5	**Long term debt to working capital** (Non-current borrowings+Current maturities of long term borrowings)/Current assets - (Current liabilities-Current maturities of long term borrowings)	4.04	5.72	1.88	4.04	1.88	11.98
6	**Bad debts to accounts receivable ratio** (Bad debts/Trade receivables)	-	-	-	-	-	-
7	**Current liability ratio** (Current liabilities/Total liabilities)	0.33	0.24	0.26	0.33	0.26	0.29
8	**Total debts to Total assets** (Total borrowings/Total assets)	0.37	0.39	0.36	0.37	0.36	0.40
9	**Debtors turnover (No. of days)** (Gross sales/Average trade receivables*No. of days)	20.32 (annualised)	31.41 (annualised)	80.41 (annualised)	28.23 (annualised)	113.10 (annualised)	25.88 (annualised)
10	**Inventory turnover (No. of days)** (Cost of materials consumed+Purchases of stock-in-trade+Change in inventories)/Average inventory*365/No of days of applicable period)	0.06 (annualised)	0.07 (annualised)	0.06 (annualised)	0.06 (annualised)	0.06 (annualised)	0.04 (annualised)
11	**Operating EBITDA margin (%)** (Profit before interest, tax, exceptional items and depreciation/Revenue from operations)	67.50%	70.86%	(12.49%)	69.34%	29.13%	48.89%
12	**Net profit margin** (Net profit for the period or year/Revenue from operations)	16.71%	112.00%	(78.41%)	68.93%	(22.39%)	2.20%
13	**Paid up equity share capital** (face value of Rs. 10 per share)	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37
14	**Other equity excluding revaluation reserves**	(2,959.61)	(3,145.55)	(5,317.25)	(2,959.61)	(5,317.25)	(4,656.71)
15	**Capital redemption reserve**	NA	NA	NA	NA	NA	NA
16	**Networth (As per Companies Act 2013)**	23,080.76	22,894.82	20,723.12	23,080.76	20,723.12	21,383.66
17	**Securities Premium**	82,533.81	82,533.81	82,533.81	82,533.81	82,533.81	82,533.81
18	**Debenture Redemption Reserve**	NA	NA	NA	NA	NA	NA

Place : Hyderabad
Date : 13-11-2026

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

For Evervie Health Limited (formerly PVP Ventures Limited)

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:23:34 +05'30'

CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

Anand Seethakathi Business Centre, 2nd Floor, No. 684-690
Anna Salai, Thousand Lights, Chennai - 600 006. India.
Tel : +91 - 44 - 4554 1480 / 81 / 82
Web : www.cngsn.com ; Email : info@cngsn.com

Limited Review Report on Unaudited Quarterly Standalone Financial Results of EVERVIE HEALTH LIMITED (formerly PVP Ventures Limited) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To

Board of Directors of Evervie Health Limited (formerly PVP Ventures Limited)

We have reviewed the accompanying statement of unaudited standalone financial results of **EVERVIE HEALTH LIMITED** (formerly PVP Ventures Limited) ("the company") for the quarter and six months ended 30th September 2026 ("the statement"), being submitted by the Company's Management pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and in accordance with the recognition and measurement, principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results,

prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for M/s **CNGSN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S / S200036

K.PARTHASARATHY
Partner
Membership No: 018394
UDIN: **26018394CTMBFD4434**

Place: Chennai
Date: 13/11/2026

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervievehealth.com

CIN:L72300TN1991PLC020122

Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

Sl No	Particulars	Quarter ended			Half year ended		Year ended
		September 2026 (Unaudited)	June 2026 (Unaudited)	September 2025 (Unaudited)	September 2026 (Unaudited)	September 2025 (Unaudited)	March 2026 (Audited)
1	**Income**						
	(a) Revenue from operations	4,807.95	4,563.69	1,709.22	9,371.64	3,430.33	8,971.09
	(b) Other Income	381.61	2,583.01	389.34	2,964.62	762.87	2,325.12
	Total Income (1)	**5,189.56**	**7,146.70**	**2,098.56**	**12,336.26**	**4,193.20**	**11,296.21**
2	**Expenses**						
	(a) Cost of materials consumed	1,181.73	898.68	115.84	2,080.41	181.32	1,435.50
	(b) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(25.29)	74.07	67.68	48.78	142.96	237.53
	(c) Employee benefit expenses	979.43	836.84	366.00	1,816.27	704.74	1,931.00
	(d) Finance Cost	1,058.74	1,014.32	843.72	2,073.06	1,670.92	3,350.31
	(e) Depreciation and Amortization expenses	583.86	613.70	141.54	1,197.56	242.97	1,367.05
	(f) Other Expenses	1,483.86	1,424.18	921.17	2,908.04	1,657.69	3,407.90
	Total Expenses (2)	**5,262.33**	**4,861.79**	**2,455.95**	**10,124.12**	**4,600.60**	**11,729.29**
3	**Profit / (Loss) before exceptional items and tax (1-2)**	**(72.77)**	**2,284.91**	**(357.39)**	**2,212.14**	**(407.40)**	**(433.08)**
4	Exceptional Loss / (Gain)	-	1,085.00	-	1,085.00	-	305.53
5	Share of profit/loss of associates, net of tax	-	-	-	-	-	(108.16)
6	**Profit / (Loss) before tax (3-4+5)**	**(72.77)**	**1,199.91**	**(357.39)**	**1,127.14**	**(407.40)**	**(846.77)**
7	**Tax expense**						
	a) Current Tax	96.10	57.26	62.29	153.36	72.77	121.16
	b) Deferred Tax	62.86	36.34	(227.27)	99.20	(276.27)	(38.71)
	c) Prior Period Deferred Tax	-	-	67.37	-	67.37	67.13
	Total Tax expense	**158.96**	**93.60**	**(97.61)**	**252.56**	**(136.13)**	**149.58**
8	**Net Profit / (Loss) for the period / year (6-7)**	**(231.73)**	**1,106.31**	**(259.78)**	**874.58**	**(271.27)**	**(996.35)**
9	**Other Comprehensive Income**						
	(A) Items that will not be reclassified to profit or loss						
	(i) Remeasurement of defined benefit liability	-	-	-	-	-	(5.82)
	(ii) Income tax expense relating to the above	-	-	-	-	-	(0.16)
		-	-	-	-	-	**(5.98)**
	(B) Item that will be reclassified to profit or Loss						
	(i) Fair value gain/(loss) on equity investments classified as FVTOCI	-	-	34.21	-	47.83	309.49
		-	-	**34.21**	-	**47.83**	**309.49**
	Total Other Comprehensive Income/ (Loss) (9)	-	-	**34.21**	-	**47.83**	**303.51**
10	**Total Comprehensive Income / (Loss) (8+9)**	**(231.73)**	**1,106.31**	**(225.57)**	**874.58**	**(223.44)**	**(692.84)**
11	**Net Profit attributable to:**						
	a) Owners of the Holding Company	(102.09)	1,208.22	(317.50)	1,106.13	(288.64)	(679.84)
	b) Non controlling interest	(129.64)	(101.91)	57.72	(231.55)	17.37	(316.51)
		(231.73)	**1,106.31**	**(259.78)**	**874.58**	**(271.27)**	**(996.35)**
12	**Other Comprehensive Income / (Loss) attributable to:**						
	a) Owners of the Holding Company	-	-	34.21	-	47.83	303.67
	b) Non controlling interest	-	-	-	-	-	(0.16)
		-	-	**34.21**	-	**47.83**	**303.51**
13	**Total Comprehensive Income/(Loss) attributable to:**						
	a) Owners of the Holding Company	(102.09)	1,208.22	(283.29)	1,106.13	(240.81)	(376.17)
	b) Non controlling interest	(129.64)	(101.91)	57.72	(231.55)	17.37	(316.67)
		(231.73)	**1,106.31**	**(225.57)**	**874.58**	**(223.44)**	**(692.84)**
14	Paid-up equity share capital (Face Value of Rs. 10/- each)	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37
15	Reserves (Other Equity)						(4,216.80)
16	Earnings per share (Face Value of Rs. 10/- each)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic (in Rs.)	(0.04)	0.46	(0.12)	0.42	(0.11)	(0.26)
	(b) Diluted (in Rs.)	(0.04)	0.46	(0.12)	0.42	(0.11)	(0.26)

Place: Hyderabad
Date : 13-11-2026

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:24:55 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervichealth.com
CIN:L72300TN1991PLC020122

Notes to Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30 September 2026

(All amounts are in Lakhs unless otherwise stated)

1 The above Consolidated Unaudited Financial Results of Evervie Health Limited (formerly PVP Ventures Limited) ('the Holding Company') and its subsidiaries (together referred to as the "Group") for the quarter and half year ended 30 September 2026 have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") as prescribed under Section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements Regulations), 2015, as amended, ("the Listing Regulations") which were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 13 Novemebr 2026. The Statutory Auditors of the Holding Company have carried out limited review of the results for the quarter and half year ended 30 September 2026.

2 The Holding Company had invested in 24,832; 22% Secured Redeemable Non-Convertible Debentures (NCDs) of Rs. 100,000 each issued by New Cyberabad City Projects Private Limited ("NCCPL"), erstwhile subsidiary and currently a related party of the Holding Company. Further, on 16 March 2015 the said investment of Rs. 24,832 Lakhs in debentures was converted to an Interest Free Secured loan against the security of Land owned by NCCPL and Land development rights available with NCCPL , repayable on 31 March 2017 which was further extended by 10 years to 31 March 2027. A further extension of 1 year until 31 March 2028 was granted vide supplementary agreement dated 07 February 2024. The outstanding principal loan amount as on 30 September 2026 is Rs. 21,843.49 Lakhs.

Though NCCPL is not carrying any business activity, based on the below-mentioned factors, the Holding Company believes that while there could be a further extension of the tenor beyond the stipulated date of 31 March 2028, the amounts are fully recoverable and hence there is no necessity to create an allowance for Expected Credit Loss.

i. Market value of a nearby land serving as a proxy to the land over which development rights held by NCCPL.
ii. Business plans of NCCPL to monetise the land bank by developing residential and/or commercial properties.
iii. Enforceable clause in the Share Purchase Agreement (SPA) which provides the first priority repayment of the loan based on the cash flows to be generated out of the project to be developed as stated in (ii) above. Additionally, the Holding Company is guaranteed 50% payout from the revenues generated in excess of the loan outstanding, out of the sale/development of the aforesaid properties.

The Holding Company believes that the provisions of Section 186(1) & 188 of the Act have been complied with to the extent applicable.

Further based on internal assessment/professional opinion received in this regard, the other provisions of Section 186 of the Act in respect to loans, making investments, providing guarantees and securities are not applicable to the Holding Company as it is involved in the business of providing infrastructural facilities.

3 The Holding Company was treating the aforesaid loan as deemed investment in subsidiary and hence was carrying the same at cost until 30 September 2023. Consequent to NCCPL ceasing to be a subsidiary as highlighted above, the Holding Company has carried the same at amortized cost as at 30 September 2026 in accordance with the requirements of Ind AS-109 – Financial instruments. Accordingly, the Management has carried the loan at present value by discounting the future cash flows at a rate of 8% over an estimated repayment period of 8.5 years (considering the possibility of further extension as stated above as against the balance legal tenor of 4 years).

The accounting has been done in the following manner:

Particulars	Remarks	Amount upon initial recognition	Amount carried as at 30 September 2026
Carried as Loan under Non-Current financial assets	Interest income has been recorded under the Effective Interest Rate (EIR) method*	11,091.29	14,088.56
Carried as Prepayment asset under other Non-Current Assets	Amortization would be done in proportion of revenues accruing to the Holding Company as per the SPA as stated in Note 2 (iii) above	10,752.20	10,752.20
		21,843.49	

* An amount of Rs. 303.03 Lakhs and Rs. 550.63 Lakhs has been recognized as Interest Income under Other Income for the quarter and half year ended 30 September 2026 respectively.

4 During the quarter ended 30 June 2026, the Holding Company acquired additional 4,263 shares representing an additional stake of 7.99% of the paid up share capital of 7Med India Private Limited (7 Med) for a consideration of Rs. 1,926.24 Lakhs. Accordingly, the Holding Company now holds 41.23% in 7 Med. The effective date of additional investment has been considered as 1 April 2026.

5 During the quarter ended 30 September 2026, 7Med India Private Limited ("7 Med"), a subsidiary of the Holding Company, incorporated a subsidiary, 7 Med (South) Private Limited ("7 Med South"), on 03 August 2026. 7 Med subscribed to 8,500 equity shares of Rs. 10 each, representing 85% of the share capital of 7 Med South. Accordingly, 7 Med South has become a step-down subsidiary of the Holding Company and has been included in these consolidated results from the date of incorporation. 7 Med South has not commenced operations as at 30 September 2026.

6 The Holding Company had acquired Humain Healthtech Private Limited ("HHT") in October 2023. HHT, in turn, has two subsidiaries, namely Noble Diagnostics Private Limited ("Noble") and Apta Medical Imaging Private Limited ("Apta").

In accordance with Ind AS 36 - Impairment of Assets, Goodwill is not amortised but tested for impairment and whenever there is an indication of impairment, impairment loss is recognised. Accordingly, the Holding Company carried out an assessment of the estimated recoverable amount, considering the future business plans and projected cash flows of the underlying business. Based on the assessment, the recoverable amount was determined to be lower than the carrying amount due to negative net-worth of Apta. Consequently, an impairment loss of Rs. 1,085.00 Lakhs has been recorded towards Goodwill during the quarter ended 30 June 2026.

Further, HHT has recognised an impairment of Goodwill of Rs. 508.85 Lakhs pertaining to its subsidiaries, Apta and Noble, which has been accounted in the consolidated results for the quarter ended 30 September 2026. The impairment losses have been presented as exceptional items in the Statement of Profit and Loss.

7 The Statement of Consolidated Assets and Liabilities as at 30 September 2026 and Statement of Consolidated Cash Flows for the half year ended 30 September 2026 are provided in Annexure 1 & 2 respectively.

8 The Group has identified reportable segments in accordance with Ind AS 108 - Operating Segments. Accordingly, two reportable segments, i.e. Real Estate and Health Care Services have been identified, the details of which are given in Segment Results - Annexure 3.

9 Subsequent to the half year ended 30 September 2026, the name of the Holding Company has been changed from "PVP Ventures Limited" to "Evervie Health Limited" with effect from 05 October 2026, pursuant to the fresh Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre. The Corporate Identity Number (CIN) of the Holding Company remains unchanged.

10 Previous period figures have been reclassified to conform to the current period classification/presentation.

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

For Evervie Health Limited (formerly PVP Ventures Limit

PRASAD VEERA POTLURI Digitally signed by PRASAD VEERA POTLURI Date: 2026.11.13 19:25:23 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Place : Hyderabad
Date : 13-11-2026

Evervie Health Limited (formerly PVP Ventures Limited)

Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031

Web: www.evervieheath.com

CIN:L72300TN1991PLC020122

Annexure 1 - Statement of Consolidated Assets and Liabilities as at 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

	Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
I	**ASSETS**		
(1)	**Non Current Assets**		
	(a) Property, Plant and Equipment	8,402.95	8,374.59
	(b) Capital work in progress	101.02	32.15
	(c) Right of Use Assets	1,557.03	1,643.14
	(d) Goodwill	14,546.06	15,631.06
	(e) Other Intangible Assets	5,266.55	5,821.85
	(f) Financial Assets		
	(i) Investments	631.23	594.93
	(ii) Loans	14,088.56	13,537.93
	(iii) Other Financial Assets	3,242.44	3,693.14
	(g) Income Tax Asset (net)	1,251.98	1,136.51
	(h) Deferred Tax Assets (net)	785.46	884.98
	(i) Other Non-Current Assets	12,411.95	12,395.22
	Total Non-current Assets	**62,285.23**	**63,745.50**
(2)	**Current Assets**		
	(a) Inventories	5,372.02	5,420.80
	(b) Financial Assets		
	(i) Investments	130.24	10.17
	(ii) Trade Receivables	3,178.96	2,614.54
	(iii) Cash and Cash Equivalents	3,568.08	5,096.90
	(iv) Other Bank Balances	867.08	26.60
	(v) Loans	677.86	435.54
	(vi) Other Financial Assets	417.65	3.42
	(c) Other Current Assets	1,573.66	944.47
	(d) Asset held for Sale	-	-
	Total Current Assets	**15,785.55**	**14,552.44**
	Total Assets	**78,070.78**	**78,297.94**
II	**EQUITY AND LIABILITIES**		
A	**Equity**		
	(a) Equity Share Capital	26,040.37	26,040.37
	(b) Other Equity	(3,300.60)	(4,216.80)
	Equity attributable to owners of the Holding Company	**22,739.77**	**21,823.57**
	(c) Non Controlling Interest	15,935.69	17,903.55
	Total Equity	**38,675.46**	**39,727.12**
B	**Liabilities**		
(1)	**Non Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	12,089.77	14,226.88
	(ii) Lease Liabilities	1,909.85	1,980.67
	(iii) Others financial liabilities	-	-
	(b) Provisions	94.63	140.21
	(c) Deferred tax liabilities	-	-
	(d) Other non current liabilities	9,945.40	8,668.25
	Total Non Current Liabilities	**24,039.65**	**25,016.01**
(2)	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	10,957.90	9,423.53
	(ii) Lease liabilities	89.61	86.11
	(iii) Trade payables		
	- Total outstanding dues of micro and small enterprises	6.42	6.42
	- Total Outstanding dues of creditors other than micro and small enterprises	2,632.38	2,302.16
	(iv) Other financial liabilities	453.14	417.07
	(b) Other current liabilities	649.10	933.70
	(c) Provisions	185.39	52.33
	(d) Current Tax Liabilities (net)	381.73	333.49
	Total Current Liabilities	**15,355.67**	**13,554.81**
	Total Liabilities	**39,395.32**	**38,570.82**
	Total Equity and Liabilities	**78,070.78**	**78,297.94**

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI

Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:25:39 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN : 00179175

Place: Hyderabad
Date : 13-11-2026

Evervie Health Limited (formerly PVP Ventures Limited)

Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031

Web: www.evervіehealth.com

CIN:L72300TN1991PLC020122

Annexure 2 - Statement of Consolidated Cash Flows for the period ended 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

	Particulars	For the period ended 30 September 2026	For the year ended 31 March 2026
		Unaudited	Audited
I	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Profit / (Loss) before Tax	1,127.14	(846.77)
	Adjustments for:		
	Loss on sale of investments (net)	-	305.53
	Gain on mutual funds (MTM)	(21.12)	(1.75)
	Impairment of goodwill / investment (exceptional)	1,085.00	-
	Depreciation and Amortization	1,197.56	1,367.05
	Interest Income	(71.57)	(297.46)
	Liabilities no longer required written back	-	(500.05)
	Provision for Advances no longer required written back	(2,238.46)	(242.92)
	Interest Income on Financial Assets	(613.25)	(1,155.02)
	Assets written off	-	4.89
	Other adjustments (net)	0.32	-
	Finance Cost	2,073.06	3,350.31
	Operating profit/ (loss) before working capital / other changes	**2,538.68**	**1,983.81**
	Adjustments for (increase)/decrease in operating assets:		
	Trade Receivables	(564.42)	(801.11)
	Loans	1,996.14	(1,434.31)
	Inventories	48.78	41.79
	Other non-current Financial Assets	513.32	(1,723.62)
	Other current Financial Assets	(414.23)	31.18
	Other non-current Assets	(16.73)	3,399.04
	Other current Assets	(629.19)	777.41
	Adjustments for increase / (decrease) in operating liabilities:		
	Trade Payables	330.22	(1,739.64)
	Other non-current Financial Liabilities	-	(568.65)
	Other current Financial Liabilities	36.07	(259.18)
	Non-current Provisions	(45.58)	(41.64)
	Current Provisions	133.06	48.92
	Other non-current Liabilities	1,277.15	(1,581.42)
	Other current Liabilities	(284.60)	(169.38)
	Cash (used in)/generated from operations	**4,918.67**	**(2,036.80)**
	Direct Taxes Paid (net)	(220.59)	(309.70)
	Net Cash flow (used in)/from Operating activities	**4,698.08**	**(2,346.50)**
II	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Capital expenditure towards tangible assets (including Capital advances, net of capital creditors)	(653.38)	(2,816.77)
	Payment made for Acquisition of subsidiary (net of cash)	-	(12,924.77)
	Investment in equity shares of other entities	(36.30)	220.53
	Investment in mutual funds (net)	(98.95)	-
	Interest Income Received	71.57	281.46
	Movement in other Bank Balances not considered as Cash & Cash Equivalents	(840.48)	(26.60)
	Net Cash flow (used in)/from Investing activities	**(1,557.54)**	**(15,266.15)**

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED ★

Evervie Health Limited (formerly PVP Ventures Limited)

Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervіehealth.com
CIN:L72300TN1991PLC020122

Annexure 2 - Statement of Consolidated Cash Flows for the period ended 30 September 2026

(All amounts are in Lakhs Indian Rupees unless otherwise stated)

	Particulars	For the period ended 30 September 2026	For the year ended 31 March 2026
		Unaudited	Audited
III	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Acquisition of non-controlling interest	(1,926.24)	-
	Non convertible Debentures (NCD's) issued	-	15,000.00
	Long term borrowings availed/(repaid)	(2,197.11)	4,217.20
	Short term borrowings taken/(repaid) (net)	1,534.37	1,041.36
	Payment of Lease Liabilities	(174.67)	(667.07)
	Finance costs paid	(1,905.71)	(650.19)
	Net Cash Flow From / (Used in) Financing Activities	**(4,669.36)**	**18,941.30**
IV	**Net Increase / (Decrease) in Cash and Cash Equivalents (I + II + III)**	**(1,528.82)**	**1,328.65**
V	Cash and Cash Equivalents at the beginning of the year	5,096.90	60.98
VI	Cash and Cash Equivalents On account of business combination	-	3,707.27
VII	**Cash and Cash Equivalents at the end of the year**	**3,568.08**	**5,096.90**
VII	**Components of Cash and Cash Equivalents**		
	Balances with Banks		
	-In Current Accounts and Deposit Accounts	3,568.08	5,096.90
IX	**Cash and Cash Equivalents as per Financial Statements**	**3,568.08**	**5,096.90**

Note: The above cash flow statement has been prepared under the Indirect Method as set out in Ind AS 7 - Statement of Cash Flows.

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:25:56 +05'30'

Place: Hyderabad
Date : 13-11-2026

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.evervie health.com
CIN:L72300TN1991PLC020122

Annexure 3 - Statement of Consolidated Segment Results for the quarter and half year ended 30 September 2026
(All amounts are in Lakhs Indian Rupees unless otherwise stated)

Sl No	Particulars	Quarter ended			Half year ended		Year ended
		September 2026	June 2026	September 2025	September 2026	September 2025	March 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Segment Revenue from operations**						
	Real Estate	1,112.83	1,349.27	506.96	2,462.10	1,426.24	3,292.29
	Health care services	3,695.12	3,214.42	1,202.26	6,909.54	2,004.09	5,678.80
	Total	**4,807.95**	**4,563.69**	**1,709.22**	**9,371.64**	**3,430.33**	**8,971.09**
2	**Segment Profit/(Loss) before finance and tax**						
	Real Estate	1,033.67	3,470.86	282.51	4,504.53	1,103.65	3,564.08
	Health care services	(47.70)	(171.63)	203.82	(219.33)	159.87	(646.84)
	Segment Profit/(Loss) before finance and tax	**985.97**	**3,299.23**	**486.33**	**4,285.20**	**1,263.52**	**2,917.24**
	Less: Finance cost	1,058.74	1,014.32	843.72	2,073.06	1,670.92	3,350.31
	Profit before exceptional items	**(72.77)**	**2,284.91**	**(357.39)**	**2,212.14**	**(407.40)**	**(433.07)**
	Exceptional items	-	1,085.00	-	1,085.00	-	305.53
	Share of profit of associates, net of tax						
	Health care services	-	-	-	-	-	(108.16)
	Total profit before tax	**(72.77)**	**1,199.91**	**(357.39)**	**1,127.14**	**(407.40)**	**(846.76)**
3	**Segment Assets**						
	Real Estate	55,120.08	53,119.98	42,031.33	55,120.08	42,031.33	53,739.91
	Health care services	22,950.68	23,215.14	14,229.48	22,950.68	14,229.48	24,558.03
	Total	**78,070.76**	**76,335.12**	**56,260.81**	**78,070.76**	**56,260.81**	**78,297.94**
4	**Segment Liabilities**						
	Real Estate	27,923.50	26,298.19	27,426.88	27,923.50	27,426.88	26,205.34
	Health care services	11,471.81	11,155.96	4,582.15	11,471.81	4,582.15	12,365.48
	Total	**39,395.31**	**37,454.15**	**32,009.03**	**39,395.31**	**32,009.03**	**38,570.82**

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.11.13 19:26:13 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Place: Hyderabad
Date : 13-11-2026

EVERVIE HEALTH LIMITED (FORMERLY PVP VENTURES LIMITED)

Registered Office: Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031

CIN:L72300TN1991PLC20122

Additional disclosure as per Regulation 52 (4) and 54 (2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, for the quarter and half year ended 30 September 2026

		Quarter ended			Half year ended		Year ended
S.No.	Particulars	September 2026	June 2026	September 2025	September 2026	September 2025	March 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Debt-Equity ratio**	0.60	0.60	0.77	0.60	0.77	0.60
	(Total Borrowings/Total Equity)						
2	**Debt service coverage ratio**	0.18	0.41	0.07	0.58	0.05	0.26
	(Profit before tax + depreciation + finance cost))/(over next one year - Expected interest outflow on long term borrowings including redemption premium +lease payements+Principal repayments)						
3	**Interest service coverage ratio**	0.30	0.70	0.11	1.00	0.15	0.86
	(Profit before tax + depreciation + finance cost))/(over next one year - Expected interest outflow on long term borrowings including redemption premium)						
4	**Current ratio**	1.03	1.27	1.83	1.03	1.83	1.07
	Current assets/Current liabilities						
5	**Long term debt to working capital**	2.23	2.38	1.58	2.23	1.58	2.83
	(Non-current borrowings+Current maturities of long term borrowings)/Current assets - (Current liabilities-Current maturities of long term borrowings)						
6	**Bad debts to accounts receivable ratio**	-	-	-	-	-	-
	(Bad debts/Trade receivables)						
7	**Current liability ratio**	0.39	0.30	0.25	0.39	0.25	0.35
	(Current liabilities/Total liabilities)						
8	**Total debts to Total assets**	0.30	0.31	0.33	0.30	0.33	0.30
	(Total borrowings/Total assets)						
9	**Debtors turnover (No. of days)**	6.62	6.96	11.60	6.47	11.64	6.52
	(Gross sales/Average trade receivables*No. of days)	(annualised)	(annualised)	(annualised)	(annualised)	(annualised)	(annualised)
10	**Inventory turnover (No. of days)**	0.86	0.72	0.15	0.79	0.13	0.32
	(Average inventory/(Cost of materials consumed+Purchases of stock-in-trade+Change in inventories)	(annualised)	(annualised)	(annualised)	(annualised)	(annualised)	(annualised)
11	**Operating EBITDA margin (%)**	24.71%	29.14%	13.96%	26.87%	21.68%	17.23%
	(Profit before interest, tax, exceptional items and depreciation/Revenue from operations)						
12	**Net profit margin**	-4.82%	26.29%	-15.20%	9.33%	-7.91%	-11.11%
	(Net profit for the period or year/Revenue from operations)						
13	**Paid up equity share capital**	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37	26,040.37
	(face value of Rs. 10 per share)						
14	**Other equity excluding revaluation reserves (Including Non-controlling interest)**	12,635.09	12,840.60	(1,788.60)	12,635.09	(1,788.60)	13,686.75
15	**Capital redemption reserve**	-	-	-	-	-	-
16	**Networth** *(As per Companies Act 2013)*	38,675.46	38,880.97	24,251.77	38,675.46	24,251.77	39,727.12
17	**Securities Premium**	82,533.81	82,533.81	79,382.35	82,533.81	79,382.35	82,533.81
18	**Debenture Redemption Reserve**	-	-	-	-	-	-

For Evervie Health Limited (formerly PVP Ventures Limited)

PRASAD VEERA POTLURI Digitally signed by PRASAD VEERA POTLURI Date: 2026.11.13 19:26:33 +05'30'

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175

Place: Hyderabad
Date : 13-11-2026

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

EVERVIE HEALTH LIMITED

CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

Anand Seethakathi Business Centre, 2nd Floor, No. 684-690
Anna Salai, Thousand Lights, Chennai - 600 006. India.
Tel : +91 - 44 - 4554 1480 / 81 / 82
Web : www.cngsn.com ; Email : info@cngsn.com

Independent Auditor's Review Report on the Interim Consolidated Unaudited Financial results

To The Board of Directors of Evervie Health Limited (formerly PVP Ventures Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Evervie Health Limited (formerly PVP Ventures Limited) ("the Holding Company" or "the Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and six months ended 30 September 2026, ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules thereunder and other accounting principles generally accepted in India and in Compliance with regulation 33 and 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410,"Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). A review of Interim Financial Information consists of making inquiries, primarily of Parent Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes results of the following entities:

SI. No	Name of the Entity	Relationship
1	PVP Corporate Parks Private Limited	Wholly Owned Subsidiary (100%)
2	Humain Healthtech Private Limited	Wholly Owned Subsidiary (100%)
3	Apta Medical Imaging Private Limited	Subsidiary of 2 above (51%)
4	Noble Diagnostics Private Limited	Subsidiary of 2 above (51.61%)
5	Biohygea Global Private Limited	Subsidiary (52%)
6	Optimus Oncology Private Limited	Subsidiary (56.12%)
7	7 Med India Private Limited	Subsidiary (41.23%)
8	Integrated Kidney Solutions Private Limited	Subsidiary of 7 above (100%)
9	7 Med (South) Private Limited	Subsidiary of 7 above (85%)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Other Matters

We did not review interim Financial Results of 9 subsidiaries (including 3 step down subsidiaries) whose interim financial information / results reflect total revenue of Rs. 6909.54 Lakhs for the quarter and six months ended 30th September 2026, net loss after tax of Rs. 757.72 Lakhs for the quarter and six months ended 30th September 2026, total comprehensive loss of Rs 757.72 Lakhs for the quarter and six months ended 30th September 2026 and the Group's share of net profit after tax of Rs.874.53 lakhs ended 30th September 2026, respectively as considered in the statement. These financial information have been reviewed by other auditors whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and solely based on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our review conclusion on the Statement is not modified in respect of this matter.

For M/s **CNGSN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S / S200036

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

K.PARTHASARATHY
Partner
Membership No: 018394
UDIN: **26018394CZNYWQ9892**

Place: Chennai
Date: 13/11/2026

CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

Anand Seethakathi Business Centre, 2nd Floor, No. 684-690
Anna Salai, Thousand Lights, Chennai - 600 006. India.
Tel : +91 - 44 - 4554 1480 / 81 / 82
Web : www.cngsn.com ; Email : info@cngsn.com

Independent Auditor's Certificate on Book value of Assets of the Company Contained in Columns A to J of the Statement of security cover and Statement of Compliance Status of financial covenants in respect of Listed Non-Convertible Debentures of the Company as at and for the quarter and half year ended 30th September, 2026

To

The Board of Directors

Evervie Health Limited (formerly PVP Ventures Limited)

Door No:2, 9th Floor, KRM Centre,

Harrington Road, Chetpet,

Chennai, Tamil Nadu – 600031.

The Management of Evervie Health Limited (formerly PVP Ventures Limited) ('Company') has requested M/s CNGSN & Associates, Chartered Accountants (being Statutory Auditor of the Company) to express a review conclusion on the "Security cover as per the terms of Debenture Trust Deed, book value of assets for secured Listed Non-Convertible Debentures ('NCDs') (Annexure-1), compliance with financial covenants (Annexure-2) and compliance with non-financial covenants (Annexure-3)" for the Company as at and for the quarter and half year ended 30th September, 2026 (hereinafter referred to as the "Statement").

The Statement is prepared by the Company from the audited books of account and other relevant records and documents maintained by the Company as at and for the quarter and half year ended 30th September, 2026 pursuant to requirements of Master Circular for debenture trustees bearing reference No. HO/17/11/12(2)2026-DDHS-POD1/I/22420/2026 dated 28th September, 2026 issued by Securities and Exchange Board of India in terms of Regulation 54 read with regulation 56(1)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 15(1)(t) of Securities and Exchange Board of India (Debenture Trustees) Regulations, 1993 (hereinafter referred together as the "SEBI Regulations"), as amended, for the purpose of submission to IDBI Trusteeship Services Limited, Debenture Trustee of the above mentioned Listed Non-Convertible Debentures (hereinafter referred to as the "Debenture Trustee").

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

Management Responsibility

1. The preparation of the Statement is the responsibility of the Management of the Company, including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

2. The Management of the Company is also responsible for ensuring that the Company complies with all the relevant requirements of the SEBI Regulations and General Information Document (GID)/ Key Information Document (KID) / Debenture Trust Deeds ('DTD') for the listed NCDs issued/ outstanding during the quarter and half year ended 30th September, 2026, and for providing all relevant information to the Company's Debenture Trustee. The Company's management is responsible for preparation and maintenance of the security cover and compliance with all covenants on a continuous basis as prescribed in the GID / DTDs / KID.

Auditor's Responsibility

3. Pursuant to the requirements of SEBI Regulations, our responsibility for the purpose of this certificate is to provide a limited assurance on whether the Book Value of Assets of the Company contained in Columns A to J of Statement of Security Cover, Statement of Compliance Status of financial Covenants and Statement of Compliance Status of Non-financial Covenants in respect of Listed NCDs of the Company as at and for the quarter and half year ended 30th September, 2026 are in agreement with the books of account and other relevant records and documents maintained by the Company as at and for the quarter and half year ended 30th September, 2026. This did not include the evaluation of adherence by the Company with all the applicable guidelines of the SEBI Regulations.

4. The engagement involves performing procedures to obtain sufficient and appropriate evidence to provide limited assurance on the Statement. The procedures performed for limited assurance vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.



5. The financial results for the quarter and half year ended 30th September 2026 have been audited by us, on which we have issued an unmodified opinion vide our report dated 13th November 2026. Our audit was conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, as amended.

6. We conducted our audit and obtained the explanations in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the ICAI. This Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI.

7. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Review Historical Financial Information, and Other Assurance and Related Services Engagements.

Conclusion

8. Based on the procedures performed as referred to in paragraph 4 above and according to the information and explanations and representation provided to us by the Management of the Company and subject to the notes stated in the Statement, nothing has come to our attention that causes us to believe that the Book Value of Assets of the Company contained in Columns A to J of Statement of Security Cover and information contained in the Statement of Compliance Status of financial Covenants are not in agreement with the unaudited books of account and other relevant records and documents maintained by the Company as at and for the quarter and half year ended 30th September, 2026.

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

Restriction on Use

9. This certificate is addressed to and provided to the Board of Directors of the Company solely for the purpose of onward submission to the Debenture Trustee and Securities and Exchange Board of India and should not be used by any other person or for any other purposes without our prior consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

For CNGSN & Associates LLP
Chartered Accountants
Firm Registration No: 004915S/S200036

Place: Chennai
Date: 13-11-2026

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

K. Parthasarathy
Partner
Membership No: 018394

UDIN For the annexures:

Name of the annexure	UDIN
Security Cover	**26018394BWIYRX5435**
Financial Covenant	**26018394SHCBDU6014**
Non- Financial Covenant	**26018394AKPGQK5996**

Evervie Health Limited (formerly PVP Ventures Limited)
Registered Office Door No. 2, 9th Floor, KRM Centre, Harrington Road, Chetpet, Chennai-600031
Web: www.everviehealth.com
CIN:L72300TN1991PLC020122

Statement of security cover in respect of all Listed Non Convertible Debentures (Series A - INE362A07054 & Series B - INE362A07047) as at 30 September 2026
(All amounts are in Lakhs unless otherwise stated)

Annexure 1

Column A	Column B	Column C	Column D	Column E	Column F	Column G	Column H	Column I	Column J	Column K	Column L	Column M	Column N	Column O
		Exclusive Charge	Exclusive Charge	Pari-Passu Charge	Pari-Passu Charge	Pari-Passu Charge	Assets not offered as Security	Elimination (amount in negative)	(Total C to H)	Related to only those items covered by this certificate				
Particulars	Description of asset for which this certificate relate	Debt for which this certificate being issued	Other Secured Debt	Debt for which this certificate being issued	Assets shared by Pari-passu debt holder (includes debt for which this certificate is issued & other debt with paripassu charge)	Other assets on which there is pari-Passu charge (excluding items covered in column F)		Debt amount considered more than once(due to exclusive plus, paripassu charge)		Market Value for Assets charged on Exclusive basis	Carrying/book value for exclusive charge assets where market value is not ascertainable or applicable (For Eg. Bank Balance, DSRA, market value is not applicable)	Market Value for Pari-passu charge Assets	Carrying value/book value for pari-passu charge assets where market value is not ascertainable or applicable (For Eg. Bank Balance, DSRA, market value is not applicable)	Total Value (C = K+L+M+N)
		Book Value	Book Value	Yes/ No	Book Value	Book Value						Relating to Column F		
ASSETS														
Property, Plant and Equipment		-	333.87	No	-	-	25.30	-	359.17	-	-	-	-	-
Capital Work in progress		-	-	No	-	-		-	-	-	-	-	-	-
Right of Use Assets		-	-	No	-	-	100.15	-	100.15	-	-	-	-	-
Goodwill		-	-	No	-	-	-	-	-	-	-	-	-	-
Intangible Assets		-	-	No	-	-	-	-	-	-	-	-	-	-
Intangible Assets under development		-	-	No	-	-		-	-	-	-	-	-	-
Investments		13,419.71	-	Yes	-	-	4,411.15	-	17,830.86	13,419.71	-	-	-	13,419.71
Loans		-	-	No	-	-	14,095.93	-	14,095.93	-	-	-	-	-
Inventories		1,616.61	-	Yes	-	-	2,991.57	-	4,608.18	42,670.00	-	-	-	42,670.00
Trade receivables		-	-	No	-	-	221.64	-	221.64	-	-	-	-	-
Cash and Cash Equivalents		-	-	No	-	-	1,023.56	-	1,023.56	-	-	-	-	-
Other Bank Balances		-	-				428.97		428.97					
Others		-	-	No	-	-	15,733.43	-	15,733.43	-	-	-	-	-
Total		15,036.32	333.87		-	-	39,031.70	-	54,401.89	56,089.71	-	-	-	56,089.71
LIABILITIES														
Debt securities to which this certificate pertains	Secured Non convertible Debentures	14,761.44		No	-	-	-	-	14,761.44	-	-	-	-	-
Other Debt sharing Pari Passu charge with above debt		-	-	No	-	-	-	-	-	-	-	-	-	-
Other Debt		-	-	No	-	-		-	-	-	-	-	-	-
Subordinated Debt		-	-	No	-	-	-	-	-	-	-	-	-	-
Borrowings		-	-	No	-	-	1,002.39	-	1,002.39	-	-	-	-	-
Bank		-	-	No	-	-	4,558.16	-	4,558.16	-	-	-	-	-
Debt securities		-	-	No	-	-	-	-	-	-	-	-	-	-
Others		-	-	No	-	-	-	-	-	-	-	-	-	-
Trade Payables		-	-	No	-	-	107.52	-	107.52	-	-	-	-	-
Lease Liabilities		-	-	No	-	-	144.88	-	144.88	-	-	-	-	-
Provisions		-	-	No	-	-	15.66	-	15.66	-	-	-	-	-
Others		-	-	No	-	-	10,731.08	-	10,731.08	-	-	-	-	-
Total		14,761.44			-	-	16,559.69	-	31,321.13	-	-	-	-	-
Cover on book value		1.02								3.80				
Cover on Market value														
	Exclusive security cover ra	1.02												

Note

1. The amount disclosed under Property, Plant and Equipment represents the net carrying amount (net of accumulated depreciation) of the assets which have been pledged as security against the borrowings - from bank and which is disclosed under Other Secured Debt.
2. Apart from above, the Company has provided personal guarantees of Chairman cum Managing Director and its relative for the listed NCDs. Further, a corporate guarantees of both the holding and a subsidiary Company - Humain Healthtech Private Limited (HHT).
3. The amount disclosed under Debt for which this certificate under the head investments represents the gross investment made by the Company in HHT after reducing the impairment provision provided as at 30 September 2026 (Refer unaudited financial results for the quarter ended 30 September 2026).
4. The Company carries its inventory at cost. The market value disclosed in this statement represents the amount as per the filings of the Company with the National Securities Depositories Limited (NSDL).
5. The Borrowings amount includes the interest accrued but not due and net of unamortised transaction costs which will be amortised over the tenure of the NCD's under the effective interest rate method prescribed under the applicable Indian Accounting Standards ("Ind AS").

For Evervie Health Limited (formerly PVP Ventures Limited)

Prasad V. Potluri
Chairman and Managing Director
DIN: 00179175
Place : Hyderabad
Date : 13-11-2026

EVERVIE HEALTH LIMITED

CNGSN & ASSOCIATES LLP
CHENNAI
CHARTERED ACCOUNTANTS

Evervie Health Limited (formerly PVP Ventures Limited)
Listed Non Convertible Debentures
List of Covenants **Financial Covenants**

Statement of compliance status of all financial covenants as at 30th September 2026 for Series A - INE362A07054 & Series B - INE362A07047

S.no	Part	Part	Category of Covenants	Description	Compliance with Covenants
1	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors covenant that in the event that any rules, regulations or guidelines are formulated (or modified or revised) by the central government or any Governmental Authority or entity having authority under Applicable Law in respect of creation of debenture redemption reserve applicable to the Debentures, the Company shall duly abide by such rules, regulations or guidelines and execute all such supplemental letters, agreements and deeds of modifications as may be required.	N/A
2	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors shall ensure that the Company shall deposit all cash inflows of the Project Receivables from the Project Collection Account and other Project Accounts to the Company Designated Account as specified in the Account Bank Agreement and ensure that the Project RERA Designated Account is funded in accordance with the terms of this Agreement and the JDA and that the outflows therefrom are in compliance with Applicable Laws at all times.	N/A
3	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors shall ensure that reserves required to be maintained in the Project RERA Designated Account in accordance with the JDA are maintained in accordance with the terms therein at all times.	N/A
4	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors covenant that the Company shall utilize the funds in the Company Accounts in the manner and priority as agreed to in as per the terms of this Agreement and the Account Bank Agreement.	Complied
5	Affirmative	Part I – General Covenants	Financial Covenants	Other than the reimbursements of the Promoters permitted by the Debenture Holders, no distribution shall be made to the Promoters till the entire Debenture Subscription Amount has been redeemed fully along with the Applicable IRR and Maturity Premium.	Complied
6	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors covenant that out of the aggregate Project Receivables received in the Project Collection Account (pursuant to written payment instruction of the Debenture Holders or any of its nominee), Transfer of, (i) 70% (seventy per cent) of such Project Receivables to the Project RERA Designated Account; (ii) 30% (thirty per cent) of such Project Recivables to the Project Operations Account; and (iii) statutory dues (such as Taxes, stamp duty or any other pass-through payments) received in the Project Collection Account towards onward payment to Governmental Authorities shall be done in accordance with Applicable Law by the Developer.	N/A
7	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors covenant that any amount from the Company Accounts and/or Project Accounts may be Transferred to any bank account at the instruction of the Debenture Holders to the extent of any cash being available for distribution (whether or not the conditions of Surplus Cash are fulfilled) for/against the payment/redemption of the Debenture Payments and/or Debenture Holder's Entitlement; based on approval of the Debenture Holders.	N/A
8	Affirmative	Part I – General Covenants	Financial Covenants	The Parties further agree that the Debenture Holders shall not be obligated to finance or provide any form of financial assistance for raising additional funds for the Company or provide any kind of Encumbrance over Debentures held by the Debenture Holders or to provide any guarantee in relation to any financial assistance sought by the Company from any person for raising such additional funds.	Complied
9	Affirmative	Part I – General Covenants	Financial Covenants	The Company shall pay, and the Security Providers shall ensure that the Company pays the Transaction Costs as and when required by the Debenture Holders, agents, banks or other consultants (as the case may be).	Complied
10	Affirmative	Part I – General Covenants	Financial Covenants	The Gearing Ratio shall at all times be less than or equal to 50% till the relevant Mandatory Redemption Date. For the purposes of the above clause: (a)Gearing Ratio shall mean Financial Indebtedness availed (other than that availed from Debenture Holders and that availed against Brigade development) by the Company divided by the Tangible Net-worth of the Company and to be tested half yearly. (b)Financial Indebtedness shall mean aggregate of consolidated long-term debt outstanding including current maturities whether secured or unsecured, plus consolidated short-term debt outstanding, whether secured or unsecured, plus redeemable preference shares outstanding plus corporate guarantees, accrued interest of the Debentures. (c)Tangible Net-worth shall mean the issued and paid-up equity share capital, securities premium and retained earnings minus the intangibles (including but not restricted to brand valuation, goodwill, etc.) and minus any revaluation reserves.	Complied Refer Note-1
11	Affirmative	Part I – General Covenants	Financial Covenants	The Series A Debenture Subscription Amount shall be utilized only in accordance with the Applicable Laws.	Complied Refer Note-1
12	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors covenant that their percentage shareholding (on a fully diluted basis) in the Company or in any of the other Obligors (as applicable) at all times shall not fall below their percentage shareholding (on a fully diluted basis) as on the Execution Date in the Company or in any of the other Obligors (as applicable) except with prior written consent of the Debenture Holders.	Complied Refer Note-1
13	Affirmative	Part I – General Covenants	Financial Covenants	The Company and the Obligors shall ensure that the Debenture Holders shall have viewing rights over the Project Accounts.	N/A
14	Affirmative	Part I – General Covenants	Financial Covenants	The Obligors covenant that any transfer of shares in Promoter 3 will be with the approval of the entire board of Promoter 3.	NA- Refer Note-1
15	Affirmative	Part I – General Covenants	Financial Covenants	The Company and/or Promoter 1 and/or Promoter 3 covenant that the Mauritius company administrator of Promoter 3 has the sole authority to permit the transfer of shares as per applicable laws and regulations in Mauritius.	N/A

Note:
1. We have been informed that the shareholders of the Platex Limited i.e. Promoter 3 has not transferred their shares during the quarter ended 30th September, 2026.



Evervie Health Limited (formerly PVP Ventures Limited)
Listed Non Convertible Debentures
List of Covenants

Statement of compliance status of all non-financial covenants as at 30th September 2026 for Series A - INE362A07054 & Series B - INE362A07047

S.no	Part	Part	Category of Covenants	Description	Compliance with convenants
1	Negative	Part I – General Covenants	General	The Obligors shall not, and each of the Obligor shall take all actions and exercise all rights and powers available to it to ensure and procure that the Company (as may be relevant) shall not undertake any of the actions set out below to the extent and as and when applicable, without the Debenture Holders' prior written consent:	Complied
2	Negative	Part I – General Covenants	Warranty Compliance	Enter into any action, commitment or transaction or fail to undertake actions which would constitute a violation or breach of any of the Warranties given on the Execution Date or repeated at the Allotment Date; or would constitute a violation or breach of any terms and conditions contained in the Transaction Documents.	Not applicable
3	Negative	Part I – General Covenants	Business Change	Undertake any: (i) change in the Business of the Company; or (ii) new business (other than the Business) including not limited to HDT Business, JDA, restructuring, Contracts, reorganization and diversification, acquisitions, new investments, mergers, divestments, sale or part sale, Transfer or amalgamation, of the Company.	No Changes
4	Negative	Part I – General Covenants	New Project Investment	Undertake any action in relation to investing monies for the acquisition of land, obtaining approvals of any nature from authorities, raising project finance for a new project, excluding Brigade Project, if not provided for in the business plan.	Not applicable
5	Negative	Part I – General Covenants	Capital Structure	Effect any change (including any increase or reduction in, or re-organization of in the authorized, issued, subscribed or paid up equity or preference share capital by any means whatsoever, or solicit or enter into negotiations, discussions, binding or non-binding commitments and/ or agreements relating to any such change in the share capital structure, shareholding pattern, issue of any securities (including convertible securities) or agree to any merger, amalgamation, demerger, arrangement or reorganization of the Company or undertaking any slump sale, business transfer or asset transfer transaction other than provided in this Deed.	No Changes
6	Negative	Part I – General Covenants	Share Rights	Effect any change in the face value of or the rights attached to the shares of the Company except as provided in the Deed.	No Changes
7	Negative	Part I – General Covenants	Charter Amendments	Effect any amendment or restatement of its Charter Documents otherwise than pursuant to this Deed, or certificate of incorporation as in effect on the date hereof, or any change of name, legal status, or registered office.	Complied
8	Negative	Part I – General Covenants	Auditor & Board Changes	Appointment, reappointment or change in the statutory auditor, internal auditor and project technical auditor or board of directors, or management of the Company, other nominee director or independent director or any director resigning from their respective position.	Complied
9	Negative	Part I – General Covenants	Delegation of Authority	Delegation of authority or any of the management powers, other than in the normal course of business, to any individual, or any amendments to the authority or power so delegated.	Not applicable
10	Negative	Part I – General Covenants	Guarantees	The Company providing corporate guarantee to any Person including in relation to any Affiliate or any other company and/ or the Company guaranteeing or underwriting any debt/ obligation/ indemnities of any of the Security Providers, directors, the management team of the Company or any other Person except those relating to fund raise against the Brigade Project	Not applicable
11	Negative	Part I – General Covenants	Winding Up	Present any scheme or petition for winding up or liquidation (including making any filing for voluntary liquidation or for voluntary initiation of the corporate insolvency resolution process under the IBC) or enter into any arrangement for restructuring or re-organisation which would have a similar effect.	Not applicable
12	Negative	Part I – General Covenants	Asset Acquisition/Disposal	Acquisition or disposal of (other than Brigade Project) or the agreement to acquire or dispose (directly or indirectly): (i) any legal or beneficial ownership of any securities of any company or other assets; and / or (ii) any interest in any land or property, or the acquisition, incorporation or establishment of any entity by the Company having an interest in land or property.	Complied
13	Negative	Part I – General Covenants	Indebtedness	Incur or permit to exist any Indebtedness other than the Debentures (other than for Brigade Project and routine expenses in the ordinary course of business not exceeding INR 2,00,00,000 (Indian Rupees Two Crores) in one Financial Year) and/ or create or permit to subsist any Security Interest over all or part of any of its assets (except a Security Interest over the Transaction Security).	Not applicable
14	Negative	Part I – General Covenants	Business Continuity	Cease or threaten to cease to carry on its business or undertake any unrelated new line of businesses and/ or operations which is not in accordance with the business plan.	Not applicable

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

15	Negative	Part I – General Covenants	Related Party Transactions	Enter into any contracts, sale of Units, etc. with any Related Party other than for routine expenses in the ordinary course of business not exceeding INR 2,00,00,000 (Indian Rupees Two Crores) in one Financial Year.	Not applicable
16	Negative	Part I – General Covenants	Bank Accounts	Open and close any bank accounts in relation to the Receivables other than as required under and pursuant to the Transaction Documents.	Complied
17	Negative	Part I – General Covenants	Account Signatory	Propose any change in the authorised representative appointed as the signatory to the Company Accounts or any other account opened pursuant to this Deed.	No Changes
18	Negative	Part I – General Covenants	Immovable Property	Enter into any transaction or series of transaction for carrying out any business activities on, from or in relation to any of the Immovable Property and/ or sell, assign, enter into an agreement to sell or assign or otherwise dispose of or Encumber any of the Immovable Property or other assets forming part of the Transaction Security or part thereof (or any interest therein) or any other property of the Company, other than as provided in the business plan.	Complied
19	Negative	Part I – General Covenants	Accounting Policies	Change in the accounting policies presently followed except as required under Applicable Law.	No Changes
20	Negative	Part I – General Covenants	Financial Year	Change its Financial Year.	No Changes
21	Negative	Part I – General Covenants	Material Adverse Effect	Permit to exist one or more events, conditions, or circumstances, which have had or continue to have or in the sole judgement of the Debenture Holders, could be reasonably expected to have a Material Adverse Effect.	Not applicable
22	Negative	Part I – General Covenants	Treasury Transactions	Enter into any treasury transactions, including any hedging or swap arrangements.	No
23	Negative	Part I – General Covenants	Creditor Role	Be a creditor in respect of any Indebtedness except for an amount not exceeding INR 1,00,00,000 per annum (it is hereby clarified that the collection from casa project or HDT Business shall not be used for the same).	Complied
24	Negative	Part I – General Covenants	Insurance Policies	Terminate, cancel or suspend for any reason any insurance policy in which the Secured Parties and/or Obligors have been named as the loss payee in accordance with this Deed, unless such termination, cancellation or suspension is initiated by the insurer. Any change in the insurance availed by the Company pursuant to the terms of this Deed.	Not applicable
25	Negative	Part I – General Covenants	Subsidiaries & Investments	Setting up subsidiaries of the Company or investments by the Company in other entities other than health care investment by the Company in the manner contemplated in Schedule 17.	Complied
26	Negative	Part I – General Covenants	Property Financing	Approval of all major property financing decisions other than as envisaged in the business plan other than the Brigade Project.	No Financing decision made
27	Negative	Part I – General Covenants	Dividend Declaration	Declare any dividend to its shareholders.	Not applicable
28	Negative	Part I – General Covenants	Director Remuneration	Payment of remuneration or distribution of profits/ commission to the directors of the Company exceeding the limits prescribed by SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.	Complied
29	Negative	Part I – General Covenants	Promoter Expenses	Reimbursement/ payment of management expenses to the Promoter and/or the Affiliates of the Company excluding in the normal course of business.	Complied
30	Negative	Part I – General Covenants	Joint Ventures	Structuring and securing any third-party joint ventures.	Not applicable
31	Negative	Part I – General Covenants	Transaction Security Disposal	Enter into a single transaction or a series of transactions (whether related or not) and whether voluntary or involuntary to sell, lease, Transfer or otherwise dispose of any asset forming part of Transaction Security.	No transaction



32	Negative	Part I – General Covenants	Related Party Compliance	Enter into any transactions with Related Parties other than on an arm's length basis and in compliance with Applicable Laws.	Complied
33	Negative	Part I – General Covenants	Litigation	Commencement, defense or settlement by the Company of any Litigation, arbitration or administrative proceeding having a material impact on the Company.	No
34	Negative	Part I – General Covenants	High-Value Contracts	The Company entering into, varying, waiving any breach of, discharging any liability under, or terminating, any contract or arrangement (whether legally binding or not) with any of its directors or shareholders or with any Affiliate or relatives of the Promoters, its value being in excess of INR 10,00,00,000 (Indian Rupees Ten Crores) in aggregate.	Not applicable
35	Negative	Part I – General Covenants	Material Contract Amendment	Amend or terminate a material contract (which in the reasonable opinion of the Debenture Holders is likely to result in a Material Adverse Effect).	Not applicable
36	Negative	Part I – General Covenants	Conflicting Agreements	Enter into any agreement that conflicts with or results in a breach of any term of the Transaction Documents	No
37	Negative	Part I – General Covenants	Board Resolutions	Adopt or join in adopting any resolution of the shareholders' or the Board which:	Not applicable
38	Negative	Part I – General Covenants	Board Resolutions	(a) in relation to the Debentures, is not contemplated by the Transaction Documents; or	Not applicable
39	Negative	Part I – General Covenants	Board Resolutions	(b) results in a breach of or in non-compliance with or conflicts with the provisions of the Transaction Documents.	Not applicable
40	Negative	Part I – General Covenants	Commitment to Restricted Actions	Agree or otherwise commit to take any actions or definitive steps to give effect to any of the matters described in the foregoing provisions in relation to Debentures, including entering into any agreement or arrangement, passing any shareholder resolution.	Not applicable
41	Negative	Part I – General Covenants	Loan Repayment Restrictions	Repayment & servicing of all loans (excluding a car loan of INR 1.4 crores from Kotak Bank) including but not limited to unsecured loans obtained by the Company from related parties using the Debenture Subscription Amount or proceeds from the Project or HDT Business.	Complied
42	Negative	Part I – General Covenants	Shareholding Dilution	None of the Obligors shall take, or omit to take, directly or indirectly any action whereby the percentage shareholding (on a fully diluted basis) of any of the Obligors in the Company or in any of the other Obligors (as applicable) is less than what they hold as on the Execution Date.	Complied
43	Negative	Part I – General Covenants	Board Constitution	Promoter 1 and Promoter 3 covenants that the board of Promoter 3 as existing as on Execution Date will not be reconstituted without the prior written consent of the Debentures Holders.	Complied



Evervie Health Limited (formerly PVP Ventures Limited)
Listed Non Convertible Debentures
List of Covenants
Statement of compliance status of all non-financial covenants as at 30th September 2026 for Series A - INE362A07054 & Series B - INE362A07047

S.no	Part	Part	Category of Covenants	Description	Compliance with convenants
1	Negative	Part II – Covenants related to HDT Business	Deployment & Guarantees	The Obligors shall not, and each of the Obligor shall take all actions and exercise all rights and powers available to it to ensure and procure that the Company (as may be relevant) shall not undertake any of the actions set out below to the extent and as and when applicable, without the Series A Debenture Holders' prior written consent:	Complied
2	Negative	Part II – Covenants related to HDT Business	Deployment & Guarantees	(a) Any deviation exceeding 5% from the deployment plan prepared and submitted by the Promoters and/or the Company to the Debenture Holders. Any exercise of the powers of the Company for providing guarantees or incemnities (including for the HDT Business).	Complied
3	Negative	Part II – Covenants related to HDT Business	Deployment & Guarantees	(b) Transfer any of the Pledged Securities.	Complied



Evervie Health Limited (formerly PVP Ventures Limited)
Listed Non Convertible Debentures
List of Covenants

Statement of compliance status of all non-financial covenants as at 30th September 2026 for Series A - INE362A07054 & Series B - INE362A07047

S.no	Part	Part	Category of	Description	Compliance with
1	Negative	Part III - Covenants related to project Casagrand Mercury Phase 3	General	The Obligors shall not, and each of the Obligor shall take all actions and exercise all rights and powers available to it to ensure and procure that the Company (as may be relevant) shall not undertake any of the actions set out below to the extent and as and when applicable, without the Series B Debenture Holders' prior written consent:	No Changes
2	Negative	Part III - Covenants related to project Casagrand Mercury - Phase 3	General	Dissolution, reconstitution, or alteration of the composition of the Project Monitoring Committee, or overruling/ deviating from any decision taken by the Project Monitoring Committee.	No Changes
3	Negative	Part III - Covenants related to project Casagrand Mercury -	General	Any exercise of the powers of the Company for providing guarantees or indemnities (including for the Project Casagrand Mercury - Phase 3).	No Changes
4	Negative	Part III - Covenants related to project Casagrand Mercury - Phase 3	General	Granting or revocation of any power of attorney or authority to any Person for the purpose of the sale of the Units in the Project Casagrand Mercury - Phase 3.	No Changes
5	Negative	Part III - Covenants related to project Casagrand Mercury -	General	Assignment of any contract or agreement connected with the rights in the Project Casagrand Mercury - Phase 3.	No Changes
6	Negative	Part III - Covenants related to project Casagrand Mercury -	General	The Company incurring costs for the Project Casagrand Mercury - Phase 3 in excess of the amounts specified in the business plan.	Not applicable
7	Negative	Part III - Covenants related to project Casagrand Mercury - Phase 3	General	Amendment of any term or revocation of the power of attorney in favour of the Debenture Holders or any Person nominated by the Debenture Holders authorizing the sale of Units in the Project Casagrand Mercury - Phase 3.	Not applicable
8	Negative	Part III - Covenants related to project Casagrand Mercury - Phase 3	General	Any change in the Minimum Sale Price or any sale of Units of the Project Casagrand Mercury - Phase 3 below the average minimum sale price, evaluated over 6 months.	No Changes

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

Evervie Health Limited (formerly PVP Ventures Limited)
Listed Non Convertible Debentures
List of Covenants

Statement of compliance status of all non-financial covenants as at 30th September 2026 for Series A - INE362A07054 & Series B - INE362A07047

S.no	Part	Part	Category of Covenants	Description	Compliance with convenants
1	Affirmative	Part II – Covenants related to HDT Business	HDT Business Covenants	The Parties agree that the HDT Business will be undertaken basis a business plan mutually agreed by the Series A Debenture Holders and the Promoters within the maturity dates as per schedule provided in Schedule 11 (Business Plan). The Parties may appoint and deploy necessary resources to manage the HDT Business.	Complied
2	Affirmative	Part II – Covenants related to HDT Business	HDT Business Covenants	The Obligors covenant that the HDT Receivables be Transferred to the Company Designated Account for/ against the payment/ redemption of the Debenture Payments and/ or Debenture Holder's Entitlement.	Complied
3	Affirmative	Part II – Covenants related to HDT Business	HDT Business Covenants	The Obligors shall ensure the following conditions are adhered for each potential acquisition pursuant to the HDT Business and the process set out in Clause 30.3 will be followed for each such acquisition using the Series A Debenture Subscription Amount:	Complied

Parameter	Qualifying Criteria for potential investments in the HDT Business
Brand recall in local market	1. The brand must be well recognized in the local market amongst consumers and doctors and should be a well-established business in the space. 2. Must have a reputation for quality and dependability and preferably NABH or NABL certified or eligible to be certified.
No Single doctor dependence	1. The target should not be dependent on a single doctor's (owner) rolodex for business. 2. Must have a sales team or direct walk ins which brings in revenues through an established go to market process with minimum contribution of 10% of revenue.
Points of presence	1. Multiple labs and/or centers in the local geography; makes it easier to achieve scale economies on fixed costs and lowers competitive intensity, with minimum 3 labs or centres.
Diversified revenue streams	1. For pathology & diagnostics, established multiple revenue streams which include doctor referral, Hospital lab management, walk ins, wellness, pricking points, collection centers, home collection etc. with no particular stream contributing to more than 85% revenue. 2. Open to both pathology and integrated diagnostics (radiology plus pathology) depending on the local dynamics
Potential to expand in the state	1. Ability to expand the brand into other parts of the state; prefer to have one brand per state and use the target as the local platform to bolt on acquisitions or expand organically in other parts of the state by acquiring other players of a similar size.
Motivated promoter/ management	1. As the acquisition methodology includes earn outs linked to future profitability, the management and promoters need to be motivated to build the business with promoters being left with minimum 25% of the equity and put option to Evervie Health Limited (formerly PVP Ventures Limited) to put the equity at a pre-determined price which will be dependent on business growth & profitability metrics. 2. As primary capital is growth capital although most deals may have a component of secondary stake purchase as well. This could be as high as 50-60% of Evervie Health Limited's investment (formerly PVP Ventures Limited) but preference shall be primary infusion of capital. Deal contours are mostly deal specific and cannot be generalized.
Profitability	1. Business should be currently profitable (minimum double digit EBITDA margins).
Reasonable Valuation	1. Value creation driven by arbitrage with multiple not exceeding 15X of EBITDA for self-operated centers.

S.no	Part A	Part	Category of Covenants	Description	Compliance with convenants
1	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	The Parties agree that the Project Casagrand Mercury - Phase 3 will be developed and executed basis a business plan mutually agreed by the Series B Debenture Holders and the Promoters within the maturity dates as per the construction schedule provided in Schedule 11 (Business Plan). The Parties may appoint and deploy necessary resources to manage the Project Casagrand Mercury - Phase 3.	Complied
2	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	The Company shall submit to the Debenture Holders, an unaudited balance sheet and profit and loss account of the Company for the preceding Financial Quarter within 30 (thirty) days from the end of such Financial Quarter.	Complied
3	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	The Company shall submit to the Debenture Holders the audited balance sheet and financial statements of the Company for a Financial Year within 90 (Ninety) days from the end of such Financial Year.	Complied
4	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	The Parties agree that the Promoters are identified as the key person(s) for the purpose of the Project Casagrand Mercury - Phase 3.	Complied
5	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	The Obligors covenant that the Project Monitoring Committee shall have been duly constituted by authority of the Board and be comprised of at least one representative and one observer appointed by each of the Series B Debenture Holders and the Company. The Project Monitoring Committee shall be authorized to oversee the development of the Project Casagrand Mercury - Phase 3 in accordance with the Approved Business Plan.	Complied

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

6	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	The Obligors covenant that the details of transfer, distribution, redemption, expenditures and estimated expenses with respect to the Project Casagrand Mercury - Phase 3 (from each relevant account including the Project Collection Account and the Project RERA Designated Account and the Project Operations Account) will be presented on an on-going basis to the Project Monitoring Committee prior to the meetings and the committee will meet at a minimum quarterly frequency or as mutually agreed between the members of the committee.	Complied
7	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	The Obligors and/ or the Company shall sell Units built as part of the Project Casagrand Mercury - Phase 3 at price per RERA saleable square foot which shall not be less than the minimum sale price and may not exceed the maximum sale price as specified below:	Complied

	Minimum Sale Price	Maximum Sale Price
Residential Area	INR 8,000/Sq. Ft.	INR 12,000/Sq. Ft.

S.no	Part A	Part	Category of Covenants	Description	Compliance with convenants
8	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and execution of the Project Casagrand Mercury - Phase 3	In the event the Obligors and/ or the Company are unable to achieve the minimum sales collection set out in Schedule 21 (Repayment Plan) Scenario - 1, then the Obligors shall infuse the deficit amount on or prior to quarterly payout date. The Obligors will infuse the shortfall for the sales made below minimum sale price into the Company Designated Account on quarterly basis. Further, for any sale of Units of the Project Casagrand Mercury - Phase 3 made below the minimum sale price (set out in this clause) which shall not exceed: (I) 15% variation from the minimum sale price for the first year from the Allotment Date and (II) 10% variation from the minimum sale price from the second year, the difference of the minimum sale price less sales price shall be deposited in the Company Designated Account or any other bank account as advised by the Series B Debenture Holders within 45 (Forty Five) days from the date of issue of Unit Sale NOC. Any change in the Minimum Sale Price or any sale of Units of the Project Casagrand Mercury - Phase 3 below the average minimum sale price will be evaluated over past 6 months sales price. The deficit amount infused by the Obligors as above, against the minimum sales collection will be adjusted against shortfall reimbursement for sales made below Minimum Sale Price. The Series B Debenture Holders shall at its sole discretion have the authority to modify the minimum sale price and the maximum sale price and the Series B Debenture Holders shall forthwith notify the Obligors regarding any such change. The Parties agree and acknowledge that the Minimum Sale Price set out above shall be subject to increase by 3% (three percent) every year. The rate will be reviewed by the Series B Debenture Holders or at an earlier date, at is sole discretion. It is clarified that for the Project Casagrand Mercury - Phase 3, the above-mentioned minimum sale price shall be deemed to be effective from Allotment Date. The Obligors shall also deposit any shortfall between the minimum sale price and the actual sale price for the Units sold prior to Allotment Date in the Company Designated Account.	Not applicable
9	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Obligors will provide access to the Series B Debenture Holders (including its consultants) to the accounting package and the enterprise resource planning software implemented by the Company used for the construction/ development of the Project Casagrand Mercury - Phase 3 and sales of the Units.	Not applicable
10	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Obligors shall ensure that the Project Casagrand Mercury - Phase 3 will be completed within 5 (five) years from the Allotment Date.	Complied
11	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Company and Obligors hereby agree and covenant that other than the Transaction Security the land underlying Project Casagrand Mercury - Phase 3 will be free from any charge or encumbrances and they shall have unrestricted access to the same.	Complied
12	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Company shall obtain a no-objection certificate or permission of the Series B Debenture Holders (or any of its nominee, representative, authorized person or any other person as identified by the Series B Debenture Holders) for sale of any Units (pertaining to security created on the Project Casagrand Mercury - Phase 3) in the format agreed by the Series B Debenture Holders.	Not applicable
13	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	If the Company has more than one project pursuant to the Series B Debenture Holders' approval, in such case the Security Providers hereby agree and covenant that the books for the Projects will be maintained separately as per the requirement under (Indian) Income Tax Act, 1961 and under the RERA.	Not applicable
14	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Obligors shall ensure that all amounts receivable from the Project are deposited/ received in the Project Collection Account till the completion of the construction of the Project Casagrand Mercury - Phase 3 and then into the Company Designated Account in the manner set out in the Accounts Agreement.	Not applicable

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS

15	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Company shall ensure that it has at all times a clear and marketable title, free from encumbrances, claims, disputes with free, independent, and unrestricted access to the Project Land.	Complied
16	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Company shall appoint the internal and project technical auditors as well as Environment, Social and Governance (ESG) consultants, for the Project Casagrand Mercury - Phase 3, with the prior consent of and in consultation with the Debenture Holders.	Complied
17	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Obligors covenant that if Project Casagrand Mercury - Phase 3' cash flows are found to be inadequate to service the Debenture Holders Entitlement, then the Obligors shall meet such costs from their own account, subject to Series B Debenture Holders' approval.	Not applicable
18	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Obligors covenant that all the amounts received from the Unit holders of the Project Casagrand Mercury - Phase 3 and/or the Project Collection Account in respect of payment of Tax (including GST) or payments of stamp duty or any other pass-through amounts shall be used towards timely payment of statutory dues to the Governmental Authorities in accordance with Applicable Law by the Developer.	Not applicable
19	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Obligors covenant that after the completion of construction of the Project Casagrand Mercury - Phase 3, 100% (one hundred per cent) of the amount in the Project Collection Account, and the Project RERA Designated Account will be Transferred to the Project Operations Account and thereafter to the Company Designated Account in accordance with the Accounts Agreement and Applicable Law and based on approval of the relevant Debenture Holders and on such terms as approved by the relevant Debenture Holders.	Not applicable
20	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Development and excution of the project Casagrand Mercury - Phase 3	The Company shall, and the Obligors shall ensure that the Company shall, supply any information related to the customers acquiring Units in the Project Casagrand Mercury - Phase 3.	Not applicable
21	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Internal Auditor and Project Technical Auditor	Ensure that all expenditures with respect to the Project Casagrand Mercury - Phase 3 are monitored by the internal auditor and project technical auditor on basis of the breakup of the cost estimate, provided by the Developer, which is filed with RERA.	Complied
22	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Internal Auditor and Project Technical Auditor	The project technical auditor and the internal auditor shall be appointed by the Company in consultation with the Series B Debenture Holders prior to commencement of the Project Casagrand Mercury - Phase 3.	Complied
23	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Payment of Service Provider/Consultant fees	The Company shall make payments to service providers with respect to the Project Casagrand Mercury - Phase 3, including but not limited to chartered accountants, project technical auditors, Debenture Trustee, internal auditors, legal counsel, valuers in a timely fashion as more particularly described in the agreements entered into with such service providers. The statutory, internal and project technical auditor fees shall be as mutually decided by the Parties. At any given point in time if the Security Provider fail to pay the fees or claim of Service Providers/ Consultants, a penalty of 24% per annum compounded interest will be levied on the unpaid dues of the said fees or claim and the same will be adjusted from Company Designated Account while maintaining minimum balance of INR 15,00,000 (Indian Rupees Fifteen Lakhs) cumulative in the Company Designated Account at all times towards payment of fees or claims of the Service Providers. After 1 year the Debenture Holders at its sole discretion may reduce the aforesaid balance up to INR 10,00,000 (Indian Rupees Ten Lakhs). In the event the Company fails to make such payments to service providers/consultants, the Debenture Holders may at its sole discretion direct the Accounts Bank to release such payments to the service providers.	Complied
24	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Non-compete	The Obligors, Affiliates and Associate Companies shall not be involved in or carry out development of any other similar ticket size project (other than the Project Casagrand Mercury - Phase 3, in which the Series B Debenture Holders have invested and Brigade Project), either directly or indirectly, within a radial distance of 5 (Five) kilometers from the Project Casagrand Mercury - Phase 3 which may adversely affect sale of Units in the Project Casagrand Mercury - Phase 3 in the view of the Series B Debenture Holders till the sale of the Project Casagrand Mercury - Phase 3 is completed.	Complied
25	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Non-compete	The Obligors covenant that until the full redemption of the Debentures and the receipt by the Debenture Holders of the Debenture Outstandings in full, the Project Casagrand Mercury - Phase 3 and the Receivables shall be dealt with strictly in accordance with the provisions of this Deed and the Transaction Documents.	Not applicable
26	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Agreements in respect of Units	It has been agreed by and between the Parties that a written conditional No objection Certificate (Unit Sale NOC) of the Debenture Trustee (acting on the instructions of the Series B Debenture Holders) will be required prior to any sale, lease, transfer of any Unit in the Project Casagrand Mercury - Phase 3 (forming a part of the Immovable Property) and/or the Immovable Property or any part thereof or interest therein.	Not applicable
27	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Agreements in respect of Units	It has been agreed by and between the Obligors and the Debenture Trustee that the Obligors shall incorporate a clause in the sale, lease, transfer agreements of the Units stating the charge on the Units in favour of the Debenture Trustee.	Complied
28	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Agreements in respect of Units	Neither any sale / transfer (in any manner) of Units (or any interests therein) in the Immovable Property to any Transferee nor any agreements to sell flat buyer's agreement or other Transfer Document, shall be entered into by the Security Providers without obtaining the aforementioned Unit Sale NOC from the Debenture Trustee.	Complied
29	Affirmative	Part III – Covenants related to Project Casagrand Mercury - Phase 3	Agreements in respect of Units	The Obligors shall ensure the deposit of the booking amounts and Project Receivables in the Project Accounts and any Surplus Cash or Receivables to be deposited in Company Designated Account only.	Not applicable

CNGSN & ASSOCIATES LLP ★ CHENNAI ★ CHARTERED ACCOUNTANTS